SAN DIEGO, CA, Feb 24, 2011 (MARKETWIRE via COMTEX) --
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today that the Company will present at several investor conferences in March 2011.
Stephan S. Ogilvie, Senior Director of Business Development, is scheduled to present at the 2011 RBC Capital Markets Healthcare Conference at the New York Palace Hotel in New York, NY, on Thursday, March 3, 2011, at 12:00 noon ET.
Michael J. Lambert, Executive Vice President and Chief Financial Officer, is scheduled to present at the Cowen and Company Annual Health Care Conference at the Boston Marriott Copley Place in Boston, MA, on Wednesday, March 9, 2011, at 11:00 a.m. ET.
Patrick F. Williams, Vice President of Industry and Investor Relations, is scheduled to present at the Barclays Capital Global Healthcare Conference at the Loews Miami Hotel in Miami, FL, on Tuesday, March 15, 2011, at 9:30 a.m. ET.
Mr. Williams is also scheduled to present at the Roth 23rd Annual OC Growth Stock Conference at The Ritz-Carlton Hotel in Laguna Niguel, CA, on Wednesday, March 16, 2011, at 10:00 a.m. PST.
A live webcast of each of the presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentations will remain available on the website for 30 days.
About NuVasive NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedures for the spine. The Company is the 5th largest player in the $7.7 billion global spine market.
NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS(R) platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system; MaXcess(R), a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF(R), NuVasive has built an entire spine franchise. With over 65 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness(R).
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the risk that NuVasive's revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts and the risk of further adjustment, or unanticipated difficulty in selling products or generating expected profitability; the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Contact: Michael J. Lambert EVP & Chief Financial Officer NuVasive, Inc. 858-909-3394 Email Contact Investors: Patrick F. Williams Vice President, Industry & Investor Relations NuVasive, Inc. 858-638-5511 Email Contact Media: Jason Rando The Ruth Group 646-536-7025 Email Contact
SOURCE: NuVasive, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=AA36CD4456E6B112 http://www2.marketwire.com/mw/emailprcntct?id=EBCFD1D5C2E1DFF8 http://www2.marketwire.com/mw/emailprcntct?id=D83C9D5AC23A88B2